Member Info for Bluebelly

From II: Comment: PLEASE NOTE THAT THIS IS AN AMENDMENT TO MEETING ID 648327 DUE TO RECEIPT POSTPONEMENT OF MEETING DATE FROM 04 NOV 2021 TO 18 NOV 2021. ALL VOTES RECEIVED ON THE PREVIOUS MEETING WILL BE DISREGARDED AND YOU WILL NEED TO REINSTRUCT ON THIS MEETING NOTICE. THANK YOU.

It still says to be received by 12th Nov. Message received on the 16th Nov.
A right Fuster Cluck!

BB

Can the Corporate action team make a complaint on behalf of the shareholders who have not received their shares as per the Project Jupiter Document filed by Tiziana. They have failed to carryout there own instructions. Copied here: 'As soon as practicable and, in any event, no later than 14 days after the Scheme Effective Date, Computershare will mail a statement by first class mail to each Scheme Shareholder holding Scheme Shares in uncertificated form providing evidence of ownership of the New Tiziana Shares such Scheme Shareholder holds.' Can our Corporate Actions Team contact Computershare, so they can tell you when these shares will now be issued and tradeable. TYIA

BB

Is this being driven down due to the next fund raise being required, or just to allow II's a seat at the table. We are at 25% of the previous raise. There can't be much trust for GC's plans of the last 18 months as most targets have been missed or delayed substantially and the money appears to decay with no actions /trials occurring. On the surface, it is looking like a lifestyle company. What have the following been doing?
'Dr Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company's pre-clinical and clinical drug development programs and associated intellectual property.'
'Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics - Dr Graham was VP of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc., where he managed and oversaw a large portion of the Regeneron pipeline portfolio including leading the immunology and inflammation antibody products across all stages of development from preclinical to post-launch'.
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs.
'Dr. Schutz has over 19 years of pharmaceutical industry experience including 14 years of Regulatory Affairs experience. He has focused on disease indications with high unmet medical needs, in Neurology (including multiple sclerosis), Pulmonology (including infectious disease), and other potential disease indications, which the Company is currently developing products for or is planning to pursue. Specifically, Foralumab (an intranasally delivered, next generation, fully human anti-CD3 monoclonal antibody) for Secondary Progressive Multiple Sclerosis (SPMS) and COVID-19 with Pulmonary Inflammation as lead indications.'

It would be good to get an update on what all these extra Board members have been getting up to.
They all look superb on paper, but they don't come for free!

BB

Whilst the majority of shareholders cannot trade their shares.

BB

FIREGUYUK: So they want 20 of our UK shares for only 1 US share
They want 20 UK shares for only 1 new US listed share.
They also want 10 US Old shares (ADR's) for 1 new listed US share.
So the new shares would trade today at 10 x the Accustem OTC pinks price - $2.12

BB

What will it be?

BB

Understood
Cheers LDJ

BB

Leddachjack: Have just transfered them all out of my ISA into my trading account. Guess I may lose about 500 quid short term but feel happier myself just running with it !!

Why do you lose £500 due to the transfer to your trading account?
I have transferred my 30,000 Accustem shares to my trading account from my ISA.

BB

$0.05/ADR is a very high charge when the ADR's are trading at $0.235 SP
If there is a similar charge for the new Accustem shares, at least you will have a 90% reduction in that fee.
30,000 divided by 2 = 15,000 ADR's currently
or
30,000 divided by 20 = 1500 new Accustem shares

BB

Your Uk Accustem shares will get{:
1 current ADR shares for 2 uk Accustem shares held, they are then sold and cash minus fees credited to your account.
If you hold you will get 1 new Accustem share for every 20 uk Accustem held . These may not be tradeable initially and could be removed from your ISA/SIPP, at worse you could get a share certificate (guessing).
If you currently hold ADR's, you will receive 1 new Accustem share for every 10 ADR's. These again, may not be tradeable initially and could be removed from your ISA/SIPP, at worse you could get a share certificate.

All IMHO

BB

Make that $750
& $75
Even more of a saving.

BB

At the moment I have 30,000 shares costing $375 to change to 15,000 ADR's plus fees.
After 1:20 consolidation I will have 1500 ADR's and $37.50 plus fees.
I think I'll take the default option and see where this goes.
They may be removed from my ISA, but I can't see any capital gains tax implications on 1500 shares in the near term.

BB

SJ1
It was reported to shareholders how the process would go. However the Nasdaq hasn't improved anything wrt TLSA SP. I see 4D had a nice rise on no news (50%). Hoping for similar rise here one day!

BB

No improvement in SP
All trials listed for October missed and no reasons given. Poor form

BB

You shouldn't need to do anything if they were held in a Crest Account. Mine are with II and it still shows Accustem and TLSA in my ISA but no value yet. You could ask for a share certificate to then add to a portfolio - maybe.
Sorry I can't be of more help.

BB

SK.
I believe it will be the same as the TILS to TLSA scenario. However that has entered week 3 now and not concluded yet!

BB

Schomosport: I posted this a couple of day ago:
'From Corporate actions:
'The New Tiziana shares are to be issued to us by DTC statement approximately 14 days after the effective date. Once received we will arrange to deposit these with our International Custodian. During this time the stock will not be tradeable. Once the shares have been deposited, they will be issued to entitled holders. These will then be tradeable and attract a live price on portfolios.'

Approximately 14 days to issue to brokers, then.
We will arrange to deposit with our International Custodian, then.
Once the shares have been deposited, they will be issued to entitled holders, then.
These will then be tradeable and attract a live price on portfolios.

So almost definitely not for another couple of weeks!!!!!'

Hope that helps explain why we haven't received them within 14 days from Scheme effective date 21st Oct .

Maybe our shares will turn up this week..

BB

They're 50% of their high from July / August
But 66% up from their low from October.
Hope that helps!!!!
Overall they're well down as TLSA are: 75% / 50% / 25% . I have bought at the lower level, so hopefully, I may see a profit soon. £1 and onwards as a combined price for Accustem & Tils wil be ok.

BB

Whoops. I left out the link to the IPO raise:
https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-announces-pricing-upsized-initial-public

BB

A recent IPO on Nasdaq 29th Oct - Entrada Therapeutics Inc trading around $700m:
https://www.entradatx.com/pipeline Not very far down the line, but they raised $180m through the IPO.
Giving it a value of $500m for the pipeline, TLSA pipeline is possibly valued around $125m and accustem at $20m.
I see us as well under valued.

BB